Pyxis Oncology, Inc. engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106,an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors.
